Athero Review - Issue 3/2020

Editorial

141

Michal Vrablík

Guidelines

147

Genetic testing of familial hypercholesterolemia in clinical practice: statement of Czech Society for Atherosclerosis

Michal Vrablík, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Lukáš Tichý, Zuzana Urbanová Za Výbor Čsat, Jana Mašková

Reviews

158

Impact of SGLT2 inhibitors and real clinical practice

Branislav Vohnout, Jana Lisičanová, Andrea Havranová

163

Hypertriglyceridemia – today and tomorrow

Martin Šatný, Michal Vrablík

168

Selected biomarkers associated with atherosclerosis and bone metabolism

Katarína Demková, Ivan Tkáč

173

Patient variability in nutritional case reports

Věra Boháčová, Tamara Starnovská

Clinical Studies

176

Mendelian randomisation studies: principle and selected examples from cardiovascular medicine

Jaroslav A. Hubáček

181

GLP-1 receptor agonists: antidiabetic agents with antiatherogenic effect

Ivan Tkáč

185

LIPIcontrol 2 what has changed after 3 years

Martin Šatný, Michal Vrablík

191

Novinky v liečbe evolokumabom: komentár k štúdiam VESALIUS-CV a FOURIER

Ivan Tkáč

194

News in the treatment with alirocumab presented in the congress of European Society of Cardiology 2020: comment on post-hoc analysis of the ODYSSEY OUTCOMES trial

Ivan Tkáč

197

A little change in payment means a big chance for a lot of ills

Lucie Ondřichová

From scholarly literature

200

Rešerše zajímavých článků ze zahraniční literatury

Eva Tůmová

Personal News

202

Professor Rudolf Poledne eighty-year old

Jan Piťha

Annoucements

203

Šobrův den 2020: XXXIV. konference o hyperlipoproteinemiích tentokrát virtuálně

Kristýna Čillíková

Athero Review

2020 Issue 3